Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation
Authors:
- 19 January 2022
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 164 (3) , 514-521
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriersBreast Cancer Research and Treatment, 2014
- Oral Contraceptives and Risk of Ovarian Cancer and Breast Cancer Among High-Risk Women: A Systematic Review and Meta-AnalysisJournal of Clinical Oncology, 2013
- Oral Contraceptive Pills as Primary Prevention for Ovarian CancerObstetrics & Gynecology, 2013
- Depot medroxyprogesterone acetate and epithelial ovarian cancer: a multicentre case–control studyBJOG: An International Journal of Obstetrics & Gynaecology, 2012
- Injectable and Oral Contraceptive Use and Cancers of the Breast, Cervix, Ovary, and Endometrium in Black South African Women: Case–Control StudyPLOS Medicine, 2012
- Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controlsThe Lancet, 2008
- Salpingo-oophorectomy and the Risk of Ovarian, Fallopian Tube, and Peritoneal Cancers in Women With a BRCA1 or BRCA2 MutationJAMA, 2006
- Serum and peritoneal fluid levels of levonorgestrel in women with endometriosis who were treated with an intrauterine contraceptive device containing levonorgestrelFertility and Sterility, 2005
- Prophylactic Oophorectomy in Carriers ofBRCA1orBRCA2MutationsNew England Journal of Medicine, 2002
- Progestin-Induced Apoptosis in the Macaque Ovarian Epithelium: Differential Regulation of Transforming Growth Factor-JNCI: Journal of the National Cancer Institute, 2002